Fracturas intertrocantéricas en adultos mayores: análisis de los factores de riesgo asociados con falla en la osteosíntesis con clavo cefalomedular

Objetivos: Las fracturas intertrocantéricas son cada vez más frecuentes debido al envejecimiento de la población. La osteosíntesis con clavo cefalomedular se utiliza ampliamente para tratar estas fracturas. El objetivo de este estudio fue analizar la tasa de fallas en la osteosíntesis con clavo cefalomedular y sus factores de riesgo. Materiales y Métodos: Se evaluó retrospectivamente a pacientes >75 años con fracturas intertrocantéricas tratados con clavo cefalomedular, en nuestro Centro, entre enero de 2016 y diciembre de 2019. Se analizó el ángulo cervicodiafisario de la cadera operada en el posoperatorio inmediato, la distancia puntaápice y la posición del tornillo deslizante en la cabeza femoral. Resultados: Se incluyó a 66 pacientes. Hubo 8 casos de fallas en la osteosíntesis (12,12%). Se comprobó que ciertos factores ya establecidos (distancia punta-ápice >25 mm y reducción en varo) también fueron factores de riesgo significativos para falla en la osteosíntesis, en nuestra cohorte. La posición inadecuada del tornillo deslizante fue un factor de riesgo con significación estadística en el análisis univariado, pero no en el multivariado. Conclusiones: Al tratar las fracturas intertrocantéricas con un clavo cefalomedular, la reducción en neutro o ligero valgo, apuntando a una distancia punta-ápice ≤25 mm redujo significativamente el riesgo de falla en la osteosíntesis. Hallamos que una localización superior o posterior del tornillo deslizante aumenta el riesgo de falla en la fijación, si bien la localización del tornillo no fue un factor de riesgo significativo en el análisis multivariado

Sistema constructivo ER 66

Manual de armado y catálogo de elementos del sistema constructivo para escuelas rurales ER 66.Material digitalizado en SEDICI gracias al Centro Interdisciplinario de Estudios Complejos, el colectivo ArqCom LP y el colectivo Agite.Centro Interdisciplinario de Estudios Complejos (CIEC

Sistema constructivo ER 66

Manual de armado y catálogo de elementos del sistema constructivo para escuelas rurales ER 66.Material digitalizado en SEDICI gracias al Centro Interdisciplinario de Estudios Complejos, el colectivo ArqCom LP y el colectivo Agite.Centro Interdisciplinario de Estudios Complejos (CIEC

Sistema constructivo ER 66

Manual de armado y catálogo de elementos del sistema constructivo para escuelas rurales ER 66.Material digitalizado en SEDICI gracias al Centro Interdisciplinario de Estudios Complejos, el colectivo ArqCom LP y el colectivo Agite.Centro Interdisciplinario de Estudios Complejos (CIEC

Evaluación Externa de la Universidad Nacional de Córdoba

Toda construcción institucional es producto de su propia historia, de sus condicionantes contextuales y de su interacción con el medio. Comprender el desarrollo institucional de la Universidad Nacional de Córdoba (UNC) supone atender a su historicidad, a su dilatada trayectoria, a los contradictorios procesos de su génesis y desarrollo.Fil: Cangiano, Miguel. Universidad Nacional de Córdoba; Argentina.Fil: Catalán, César. Universidad Nacional de Córdoba; Argentina.Fil: Ciuro Caldini, Miguel Ángel. Universidad Nacional de Córdoba; Argentina.Fil: Del Bello, Juan Carlos. Universidad Nacional de Córdoba; Argentina.Fil: Ciuro Caldini, Miguel Ángel. Universidad Nacional de Córdoba; Argentina.Fil: Fliess, Enrique. Universidad Nacional de Córdoba; Argentina.Fil: Garces, Luis. Universidad Nacional de Córdoba; Argentina.Fil: Ginestar, Ángel. Universidad Nacional de Córdoba; Argentina.Fil: Guerín, Miguel. Universidad Nacional de Córdoba; Argentina.Fil: Guaglianone, Ariadna. Universidad Nacional de Córdoba; Argentina.Fil: Lohe, Rodolfo. Universidad Nacional de Córdoba; Argentina.Fil: López Dávalos, Arturo. Universidad Nacional de Córdoba; Argentina.Fil: Pérez Lindo, Augusto. Universidad Nacional de Córdoba; Argentina.Fil: Pérez Rasetti, Carlos. Universidad Nacional de Córdoba; Argentina

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Documento específico (8)

Evaluación externa de la Universidad Nacional de Córdoba

Sarcomatoid differentiation in renal cell carcinoma: prognostic implications

INTRODUCTION: Renal cell carcinoma with sarcomatoid differentiation is a tumor with aggressive behavior that is poorly responsive to immunotherapy. The objective of this study is to report our experience in the treatment of 15 patients with this tumor. MATERIALS AND METHODS: We retrospectively analyzed 15 consecutive cases of renal cell carcinoma with sarcomatoid differentiation diagnosed between 1991 and 2003. The clinical presentation and the pathological stage were assessed, as were the tumor's pathological features, use of adjuvant immunotherapy and survival. The study's primary end-point was to assess survival of these individuals. RESULTS: The sample included 8 women and 7 men with mean age of 63 years (44 - 80); follow-up ranged from 1 to 100 months (mean 34). Upon presentation, 87% were symptomatic and 4 individuals had metastatic disease. Mean tumor size was 9.5 cm (4 - 24) with the following pathological stages: 7% pT1, 7% pT2, 33% pT3, and 53% pT4. The pathological features showed high-grade tumors with tumoral necrosis in 87% of the lesions and 80% of intratumoral microvascular invasion. Disease-free and cancer-specific survival rates were 40 and 46% respectively, with 2 cases responding to adjuvant immunotherapy. CONCLUSIONS: Patients with sarcomatoid tumors of the kidney have a low life expectancy, and sometimes surgical resection associated with immunotherapy can lead to a long-lasting therapeutic response